Loading…
Loading…
VOQP (VioQuest Pharmaceuticals, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
VOQP does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VOQP and 80,000+ other tickers.
See exactly how VOQP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VOQP and 80,000+ other tickers.
VioQuest Pharmaceuticals, Inc. is a biopharmaceutical entity that concentrates on obtaining, developing, and marketing drug therapies in clinical stages, specifically targeting oncology and infectious diseases. Its primary product, Xyfid, is currently being advanced for both the management and prevention of hand-foot syndrome. The company's pipeline also features VQD-002, a nucleoside analog presently in Phase I clinical trials for cancer treatment. Another key compound is Lenocta, a small molecule designed to inhibit various protein tyrosine phosphatases, which is progressing through Phase…
No recent news available.